ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Spark Therapeutics plans to spend $575 million to build a gene therapy innovation center on the campus of Drexel University. The 46,000 m2 center will be part of Spark’s 92,000 m2 campus in Philadelphia. The firm’s Luxturna retinal dystrophy treatment was the first gene therapy to win US approval, in 2017. Roche acquired Spark in 2019 for about $4.8 billion and says the new facility will serve as its global center of excellence for gene therapy manufacturing.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X